Glatiramer Acetate

Last Updated: 09/19/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 2611 publications

Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.

Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.

Journal: Health technology assessment (Winchester, England)

Published: August 11, 2026

Antigliotic guiding regenerative gel: a bioactive hydrogel platform for peripheral nerve and spinal cord repair.

Antigliotic guiding regenerative gel: a bioactive hydrogel platform for peripheral nerve and spinal cord repair.

Journal: Frontiers in surgery

Published: June 06, 2026

Mitochondrial bioenergetic remodeling underlies fingolimod-induced immunometabolic adaptation in multiple sclerosis.

Mitochondrial bioenergetic remodeling underlies fingolimod-induced immunometabolic adaptation in multiple sclerosis.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: May 08, 2026

Experimental Therapies in Multiple Sclerosis: Epstein-Barr Virus and Potential EBV-Related Therapeutic Strategies-A Systematic Review.

Experimental Therapies in Multiple Sclerosis: Epstein-Barr Virus and Potential EBV-Related Therapeutic Strategies-A Systematic Review.

Journal: Journal of clinical medicine

Published: May 03, 2026

Bridging the Pregnancy Knowledge Gap: A Real-World Analysis of Medication Use and Drug-Drug Interaction Risk in Crohn's Disease and Multiple Sclerosis.

Bridging the Pregnancy Knowledge Gap: A Real-World Analysis of Medication Use and Drug-Drug Interaction Risk in Crohn's Disease and Multiple Sclerosis.

Journal: Clinical and translational science

Published: April 15, 2026

Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in Medicare.

Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in Medicare.

Journal: Neurology

Published: April 06, 2026

Glatiramer Acetate Therapy Induces DNA Methylation Changes in Immune Cells of Multiple Sclerosis Patients: A Pilot Study.

Glatiramer Acetate Therapy Induces DNA Methylation Changes in Immune Cells of Multiple Sclerosis Patients: A Pilot Study.

Journal: International journal of molecular sciences

Published: April 02, 2026

Genetic Influences on Disease-Modifying Therapy Response in Multiple Sclerosis: Current Insights and Future Directions.

Genetic Influences on Disease-Modifying Therapy Response in Multiple Sclerosis: Current Insights and Future Directions.

Journal: Balkan medical journal

Published: April 01, 2026

Cumulative six-year safety outcomes of glatiramer acetate exposure during pregnancy and breastfeeding.

Cumulative six-year safety outcomes of glatiramer acetate exposure during pregnancy and breastfeeding.

Journal: Journal of neurology

Published: March 25, 2026

Clinical, demographic, and pharmacological predictors of medication adherence to disease-modifying therapies in multiple sclerosis: a multidimensional analysis of merged survey and claims data.

Clinical, demographic, and pharmacological predictors of medication adherence to disease-modifying therapies in multiple sclerosis: a multidimensional analysis of merged survey and claims data.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: March 10, 2026

Recommendations of Multiple Sclerosis and Neuroimmunology Section of the Polish Neurological Society and the Polish Society of Gynecologists and Obstetricians for family planning and pregnancy management in women with multiple sclerosis: an update.

Recommendations of Multiple Sclerosis and Neuroimmunology Section of the Polish Neurological Society and the Polish Society of Gynecologists and Obstetricians for family planning and pregnancy management in women with multiple sclerosis: an update.

Journal: Neurologia i neurochirurgia polska

Published: March 08, 2026

Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study.

Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: March 03, 2026

Showing 1-12 of 2,611

Last Updated: 09/19/2026